To determine whether HH-F3 treatment is able to decrease Tau phosphorylation in AD-iNs, we measured using Western blotting the amount of p-Tau relative to total Tau level in lysates from iNs derived from AD patients (Fig. 3c–e). Here, MAPT is linked to Alzheimer disease.